Jenia Gutin Email

Co-Founder and CTO . Senseera

Current Roles

Employees:
19
Revenue:
$0
About
Senseera's GEM (Genomic Expression Maps) BIOMARKERS, is a novel biomarker discovery platform based on a patent protected chromatin epigenomics (cfChIP-seq) liquid biopsy technology (Sadeh, Nature Biotechnology, 2021). \n\nGEM BIOMARKERS turns a simple blood draw into unparalleled, quantitative, cell-specific gene expression, and regulation data from cell-free DNA. Going beyond traditional methods like cfDNA genomics and methylation, it offers a transformative layer of data for various applications including biomarker discovery, tissue-agnostic MRD detection, response to therapy, dose optimization, disease subtyping and more.\n\nBacked by a database of over 20,000 annotated disease samples and a 2,000+ healthy subjects cohort, Senseera is collaborating with leading drug developers from big pharma and biotechs, to deliver mechanistic insights with exceptional sensitivity and specificity across multiple indications, advancing human health and precision medicine worldwide.
Senseera Address

Jerusalem, null
il
Senseera Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.